News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gyros AB Appoints Dr. Claus Braestrup to the Board of Directors



1/28/2013 10:22:24 AM

28 January 2013, Uppsala, Sweden: Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced Dr. Claus Braestrup has joined its Board of Directors.

Dr. Braestrup is a member of the Board of Directors of Bavarian Nordic A/S, Chairman of the Board of Probiodrug AG and a member of the Boards of Santaris Pharma A/S and Evolva Holding SA. He is also a Member of the Advisory Board of Nordic Biotech and BankInvest BioMedical Venture. Dr. Braestrup is a Member of The Royal Danish Scientific Society and The Academy of Technical Sciences. He holds M.Sc. degrees in Chemical Engineering and Biochemistry, and a Doctorate in Medical Science from the University of Copenhagen.

Dr. Braestrup was previously President and Chief Executive Officer at H. Lundbeck A/S. He also formerly held the positions of Vice President of Pharmaceutical Research, President of the CNS Division, and President of the Diabetes Care Division at Novo Nordisk A/S, and Head of Preclinical Drug Research with Schering AG.

Erik Walldén, CEO at Gyros, commented: “We welcome Claus to the Board of Directors. His excellent scientific background and many years’ experience within the biotech and pharmaceutical industry will be a great asset to Gyros.”

Katie Odgaard

Zyme Communications Ltd

Tel: +44 (0) 7787 502 947

Email: katie.odgaard@zymecommunications.com

Twitter: zymecomms

About Gyros AB www.gyros.com

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The Gyros™ immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nanoliter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is, based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors in Asia Pacific.


Read at BioSpace.com


comments powered by Disqus
Gyros AB
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES